Development of a Molecular Diagnostic Tool for Endometrial Cancer.
- Conditions
- Endometrium Cancer
- Registration Number
- NCT06192017
- Lead Sponsor
- MiMARK Diagnostics, S.L.
- Brief Summary
WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen. The aim of the study consists in validating WomEC's ELISA test, creating and freezing an algorithm to rule out EC in post-menopausal women with abnormal uterine bleeding (AUB).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 700
-
Post-menopausal women (≥1 year without menstruation) with AUB who present with:
- Endometrium > 3mm by transvaginal ultrasound, OR
- Endometrium ≤ 3mm who meet at least one of the following criteria:
i. Persistent symptoms (more than one episode of metrorrhagia) ii. Heterogenous endometrium on transvaginal ultrasonography iii. Risk factors (BMI ≥ 30, use of tamoxifen, hormone replacement therapy (HRT), Lynch syndrome, BRCA mutation.
-
Obtaining written informed consent
- Women with an active pelvic infection.
- Women who have had viral infections with evidence of active and latent disease such as Hepatitis B, Hepatitis C, and HIV infection. Patients who have had Hepatitis C in the past but who have been successfully treated and in whom viral replication has not been observed in the last year will be included.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Regulatory Requirements Study 12 months Ensure the stability of the samples under defined conditions (pre-analytica) and the analytical validation of the developed WomEC's ELISA test.
Algorithm testing and freeze 12 months To test and freeze the defined algorithm measured with MiMARK's antibodies to rule out EC in post-menopausal women with AUB.
Algorithm training with Proprietary Antibodies 12 months Train the current WomEC's algorithms defined in MS by assessing the clinical performance of different EC biomarkers individually and in combination to rule out EC in post- menopausal women with AUB using MiMARK's proprietary antibodies.
- Secondary Outcome Measures
Name Time Method Evaluation of the performance of WomEC to determine other prognostic factors of EC. 12 months Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to determine other prognostic factors of EC.
To determine the accuracy of WomEC alone for the diagnosis of EC by pipelle biopsy. 12 months Test the ability of WomEC to discriminate between EC and non-EC patients.
Evaluation of the performance of different models of WomEC to determine histological subtype. 12 months Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to determine an histological subtype.
Evaluation of the performance of WomEC to diagnose endometrial atypical hyperplasia. 12 months Calculate the sensitivity, specificity, accuracy, precision, and clinical validity of WomEC to diagnose endometrial atypical hyperplasia.
Trial Locations
- Locations (19)
Hospital Universitario de Torrevieja
🇪🇸Torrevieja, Alicante, Spain
Hospital Universitari Son Espases
🇪🇸Palma De Mallorca, Balearic Islands, Spain
Hospital Universitari de Bellvitge - Hospital Duran i Reynals
🇪🇸Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
🇪🇸Santander, Cantabria, Spain
Hospital Universitario de Donostia
🇪🇸Donostia, Guipuzcoa, Spain
Hospital Materno Infantil de Gran Canaria
🇪🇸Las Palmas De Gran Canaria, Las Palmas, Spain
Hospital Universitario de Getafe
🇪🇸Getafe, Madrid, Spain
Hospital Universitari Campus Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic
🇪🇸Barcelona, Spain
Hospital Universitario de Puerto Real
🇪🇸Cadiz, Spain
Scroll for more (9 remaining)Hospital Universitario de Torrevieja🇪🇸Torrevieja, Alicante, SpainAna María NavarroContact608330727navarro_anafen@gva.esEduardo Cazorla, PhDPrincipal Investigator